KYMERA THERAPEUTICS INC's ticker is KYMR and the CUSIP is 501575104. A total of 128 filers reported holding KYMERA THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,910,479 | -38.9% | 1,504,351 | +1.1% | 0.56% | -31.2% |
| Q2 2023 | $34,198,797 | -6.0% | 1,487,551 | +21.1% | 0.81% | -6.2% |
| Q1 2023 | $36,396,870 | +18.8% | 1,228,379 | +0.0% | 0.87% | +17.8% |
| Q4 2022 | $30,645,364 | +34.5% | 1,227,779 | +17.3% | 0.74% | +25.1% |
| Q3 2022 | $22,788,000 | +49.2% | 1,046,743 | +34.9% | 0.59% | +32.4% |
| Q2 2022 | $15,277,000 | -52.2% | 775,879 | +2.6% | 0.44% | -44.7% |
| Q1 2022 | $31,989,000 | -32.1% | 755,875 | +1.9% | 0.80% | -26.1% |
| Q4 2021 | $47,114,000 | +9.4% | 742,065 | +1.2% | 1.09% | +20.3% |
| Q3 2021 | $43,052,000 | +41.7% | 732,927 | +17.0% | 0.90% | +50.6% |
| Q2 2021 | $30,387,000 | +25.8% | 626,527 | +0.8% | 0.60% | +14.0% |
| Q1 2021 | $24,162,000 | -45.4% | 621,777 | -12.9% | 0.53% | -43.8% |
| Q4 2020 | $44,260,000 | +92.9% | 713,865 | +0.5% | 0.94% | +61.2% |
| Q3 2020 | $22,939,000 | – | 709,965 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 5,858,262 | $81,429,842 | 12.61% |
| Aquilo Capital Management, LLC | 782,219 | $10,872,844 | 9.85% |
| BVF INC/IL | 4,739,004 | $65,872,156 | 1.78% |
| Redmile Group, LLC | 1,868,507 | $25,972,247 | 1.24% |
| Artal Group S.A. | 1,805,346 | $25,094 | 1.08% |
| Deer Management Co. LLC | 615,895 | $8,560,941 | 1.04% |
| Avoro Capital Advisors LLC | 3,855,000 | $53,584,500 | 0.84% |
| Rock Springs Capital Management LP | 1,504,351 | $20,910,479 | 0.56% |
| AtonRa Partners | 19,172 | $266,491 | 0.56% |
| Baker Brothers Advisors | 4,750,400 | $66,030,560 | 0.38% |